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Inclusion of multiple high-risk histopathological criteria improves the prediction of adju-
vant chemotherapy efficacy in lung adenocarcinoma
Aims: The decision to consider adjuvant chemother-
apy (AC) for non-small cell lung cancer is currently
governed by clinical stage. This study aims to assess
other routinely collected pathological variables related
to metastasis and survival for their ability to predict
the efficacy of AC in lung adenocarcinoma.
Methods and results: A retrospective single-centre ser-
ies of 620 resected lung non-mucinous adenocarci-
noma cases from 2005 to 2015 was used. Digital
images of all slides were subjected to central review,
and data on tumour histopathology, AC treatment
and patient survival were compiled. A statistical case
matching approach was used to counter selection
bias. Several high-risk pathological criteria predict
both pathological nodal involvement and early death:
positive vascular invasion status (VI+) (HR = 2.10,
P < 0.001), positive visceral pleural invasion status
(VPI+) (HR = 2.16, P < 0.001), and solid/micropapil-
lary-predominant WHO tumour type (SPA/MPPA)
(HR = 3.29, P < 0.001). Crucially, these criteria also
identify patient groups benefiting from AC
(VI + HR = 0.69, P = 0.167, VPI + HR = 0.44,
P = 0.004, SPA/MPPA HR = 0.36, P = 0.006). Cases
showing VI+/VPI+/SPA/MPPA histology in the
absence of AC stage criteria were common (170 of
620 total), and 8 had actually received AC. This
group showed much better outcomes than equivalent
untreated cases in matched analysis (3-year OS
100.0% versus 31.3%). Inclusion of patients with
VI+/VPI+/SPA/MPPA histology would increase AC-el-
igible patients from 51.0% to 84.0% of non-mucinous
tumours in our cohort.
Conclusions: Our data provide preliminary evidence
that the consideration of AC in patients with additional
high-risk pathological indicators may significantly
improve outcomes in operable lung adenocarcinoma,
and that AC may be currently underused.
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Introduction
Adjuvant chemotherapy (AC) is now a well-estab-
lished component of therapy for non-small cell lung
cancer (NSCLC). Meta-analyses of prospective studies
show an overall patient benefit of 4–5% in 5-year
survival,1,2 and current UK and US guidelines recom-
mend AC in cases of clinical stage IIA or above,
equivalent to TNM 8th pathology staging of at least
pT2b (i.e. >40 mm) and/or positive nodal metastasis.
The biological rationale underlying the efficacy of
AC is the elimination of clinically occult metastatic
tumour cells which lies beyond the surgically resected
field. Nodal involvement and tumour size are clearly
key measures of occult metastatic potential, as nodal
involvement is direct evidence of metastasis, and for
any given invasive tumour any increase in tumour
volume offers additional opportunities for tumour
seeding. However, several other routinely collected
histological data would be expected a priori to provide
further valuable information. Vascular invasion (VI),
visceral pleural invasion (VPI), and histological
growth pattern are all good candidate additional
biomarkers of benefit. VI directly demonstrates seed-
ing into haematogenous or lymphovascular systems.
VPI shows the ability of a tumour to penetrate
through the pleural elastin layers and indicates an
elevated risk of seeding into the pleural cavity. In
adenocarcinoma, areas of in situ growth pattern are
by definition probably incapable of metastasis,
whereas all invasive patterns would be expected to
carry this risk, and high-risk growth patterns are
known to be especially likely to recur. Therefore, we
set out to determine whether these three histopatho-
logical variables, show any ability to predict beneficial
effects of AC in a large retrospective case series of
resected primary lung adenocarcinomas.
Material and methods
R E T R O S P E C T I V E C O H O R T O F L U N G
A D E N O C A R C I N O M A C A S E S
An electronic database search of the histopathology
department within the University Hospitals of Leices-
ter (UHL) NHS Trust was conducted to identify all
patients who underwent surgery with curative intent
for non-mucinous primary lung adenocarcinoma
from 2005 to 2015. Patients who had been diag-
nosed with any other lung tumour in the previous
5 years prior to diagnosis were excluded, as were
tumours with non-adenocarcinomatous elements.
The complete cohort consisted of 620 cases, of which
516 had complete data in overall stage, T stage, N
stage, VI status, VPI status and WHO subtype. These
are summarised in Table 1.
C L I N I C O P A T H O L O G I C A L D A T A
Clinical and survival data were collected from pathol-
ogy reports, local treatment databases, patient records
and Public Health England. All tissue and data were
collected under NHS ethics agreement 14/EM/1159
approved on 18th September 2014 by the Northamp-
ton committee of the National Research Ethics Ser-
vice.
409 whole section digital images of all tumour
slides were obtained using a Hamamatsu nanozoomer
XR instrument and reviewed by an experienced sub-
specialty pathologist (JLQ) to standardise microscopic
histological measures. In many cases diagnostic elas-
tin-stained slides were available for assessment and
these data were incorporated into H&E-based assess-
ment of pleural and vascular invasion. Cases of doubt
were examined by and discussed with a second sub-
specialty pathologist (DM) to obtain a consensus. All
positively identified VI was recorded, and no attempt
was made to separate haematovascular from lympho-
vascular invasion. VPI was assessed by invasion of
H&E-stained slide images and was recorded as PL0–
PL3 as originally described by Hammar et al.3 and
subsequently incorporated into TNM 7th.4
Histopathological staging was performed according to
TNM 8th. Tumours were classified by type according
to WHO criteria5: Adenocarcinoma in situ (AIS), min-
imally invasive adenocarcinoma (MIA), lepidic-pre-
dominant adenocarcinoma (LPA), acinar-
predominant adenocarcinoma (APA), papillary-pre-
dominant adenocarcinoma (PPA), solid-predominant
adenocarcinoma (SPA) and micropapillary-predomi-
nant adenocarcinoma (MPPA).
Details of the chemotherapy regimens applied are
incomplete, but in all cases where it is known (48 of
95 treated cases) patients received a standard platinum
doublet therapy. We do not anticipate that many
patients, if any, received alternative AC regimens.
To minimise selection bias, a balanced subset of the
cohort was created for each model of chemotherapy
effects. Each treated case was matched with an
untreated case matched as closely as possible for sex,
tumour size, nodal stage, VI, VPI, predominant
growth pattern and performance status, using opti-
mised smallest average absolute propensity score dis-
tance across all the matched pairs.6 The matching
process successfully reduced most absolute standard-
ised mean differences between treated and untreated
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Table 1. Patient, tumour and adjuvant chemotherapy treatment characteristics
Treated cases (n = 95) Untreated cases (n = 488) All cases (n = 620)
Age at surgery (years)
n (%) 95 (100.0) 488 (100.0) 620 (100.0)
mean (95% CI) 63.5 (49.7, 77.0) 69.2 (54.4, 82.0) 68.1 (52.0, 81.1)
Sex
Male 26 (27.4) 230 (47.1) 273 (44.0)
Female 69 (72.6) 258 (52.9) 347 (56.0)
Performance status
0 65 (68.4) 220 (45.1) 299 (48.2)
1 23 (24.2) 198 (40.6) 240 (38.7)
2 7 (7.4) 59 (12.1) 68 (11.0)
3 0 (0.0) 7 (1.4) 8 (1.3)
4 0 (0.0) 1 (0.2) 1 (0.2)
NA 0 (0.0) 3 (0.6) 4 (0.6)
Stage
0 0 (0.0) 4 (0.8) 4 (0.6)
I 8 (8.4) 240 (49.2) 260 (41.9)
II 29 (30.5) 92 (18.9) 127 (20.5)
III 51 (53.7) 83 (17.0) 148 (23.9)
NA 7 (7.4) 69 (14.1) 81 (13.1)
Tumour size (mm)
n (%) 94 (98.9) 471 (96.5) 601 (96.9)
mean (95% CI) 39.2 (14.0, 80.0) 32.3 (10.0, 70.0) 34.1 (10.0, 72.0)
T stage
T1 20 (21.0) 195 (40.0) 225 (36.3)
T2 44 (46.3) 160 (32.8) 218 (35.2)
T3 17 (17.9) 76 (15.6) 97 (15.6)
T4 11 (11.6) 30 (6.1) 49 (7.9)
NA 3 (3.2) 27 (5.5) 31 (5.0)
N stage
N0 26 (27.4) 326 (66.8) 370 (59.7)
N1 24 (25.3) 58 (11.8) 89 (14.3)
N2 51 (43.1) 52 (10.7) 101 (16.3)
NA 4 (4.2) 52 (10.7) 60 (9.7)
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groups to less than 0.10, indicating that the treated
and untreated groups are nearly balanced after
matching.
Survival models were generated by standard Cox
proportional hazards models and Kaplan–Meier meth-
ods. Proportional hazards assumptions were checked
by inspection of log-log plots and Schoenfeld residual-
based tests for Cox proportional hazards models.
Kaplan–Meier curves were compared with the (Man-
tel–Haenszel) log-rank test and the Peto & Peto test.
Compared to the log-rank test statistic, the Peto &
Peto test statistic gives more weight to earlier events,
and is thereby more sensitive to early differences
between survival. All statistical analyses were con-
ducted in R (version 4.0.2).
Results
We first established the relationships between key
pathological measures and patient survival in our ser-
ies, both in the entire cohort (Figure S1; Table S1)
and in cases not receiving AC (Figure S2; Table S2).
As expected, overall pathological stage is strongly
related to survival in both groups. We went on to
examine three more pathological measures of disease
aggressiveness: VI, VPI, and predominant growth pat-
tern. All strongly predict outcome in both univariate
(Figures S1B–D and S2B–D; Tables S1 and S2) and
multivariate analyses (Figure 1). Furthermore, while
VI status, VPI status and predominant growth pattern
are all significantly associated with tumour size and
pathological lymph node involvement (Table S3), the
association between these variables is very weak
(Table S4), implying that these three variables convey
distinct information as measures of occult metastatic
risk.
The degree of VPI shows a clear incremental rela-
tionship with poor outcome (Figures S3C and S4C),
and cases were divided into VPI+ (i.e. PL1–PL3) ver-
sus VPI cases (i.e. PL0). WHO tumour types were
grouped into precursor (MIA/AIS), low-risk (LPA),
moderate-risk (APA/PPA), and high-risk (SPA/MPPA)
groups (Figures S1D and S2D). This subdivision
Table 1. (Continued)
Treated cases (n = 95) Untreated cases (n = 488) All cases (n = 620)
Vascular invasion
Negative 42 (44.2) 260 (53.3) 319 (51.4)
Positive 53 (55.8) 225 (46.1) 298 (48.1)
NA 0 (0.0) 3 (0.6) 3 (0.5)
Pleural invasion
PL0 47 (49.5) 272 (55.8) 338 (54.5)
PL1 31 (32.6) 129 (26.4) 170 (27.4)
PL2 6 (6.3) 26 (5.3) 35 (5.7)
PL3 6 (6.3) 42 (8.6) 49 (7.9)
NA 5 (5.3) 19 (3.9) 28 (4.5)
WHO subtype
LPA 8 (8.4) 63 (12.9) 73 (11.8)
APA 44 (46.3) 193 (39.6) 249 (40.2)
PPA 14 (14.7) 70 (14.3) 89 (14.4)
MPPA 1 (1.1) 11 (2.3) 14 (2.3)
SPA 27 (28.4) 128 (26.2) 169 (27.3)
MIA/AIS 1 (1.1) 23 (4.7) 26 (4.0)
LPA, Lepidic adenocarcinoma; APA, Acinar adenocarcinoma; PPA, Papillary adenocarcinoma; MPPA, Micropapillary adenocarcinoma; SPA,
Solid adenocarcinoma; MIA, Minimally invasive adenocarcinoma; AIS, Adenocarcinoma in situ; NA, Not applicable.
© 2021 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology, 78, 838–848.
Predicting chemo efficacy in lung adenocarcinoma 841
appears natural and has been previously used in
other large studies.7–9
Given the strength of the links between these vari-
ables, metastatic potential and patient survival, we
went on to examine their potential as biomarkers of
AC efficacy. This was assessed by the construction of
survival models to test the effect of chemotherapy in
subgroups of our cohort. These analyses were further
optimised by selection of matched sets of treated and
untreated cases to eliminate treatment selection bias.
In a matched analysis of all treated cases (Figure 2;
Table 2), chemotherapy treatment was related to
improved survival (3-year OS 44.1% versus 60.6%
log-rank P = 0.005) (Figure 2A). We then compared
the chemotherapy effect in patients with and without
histopathological VI (Figure 2B,C). Chemotherapy
had no discernible effect in VI cases but a trend
toward beneficial effect of chemotherapy was appar-
ent in VI+ cases at 3 years (Figure 2C, 3-year OS
40.2% versus 56.1% Peto & Peto P = 0.053),
although significance is lost over 5 years as numbers
diminish (Figure 2C, 5-year OS 35.4% versus 37.0%
log-rank P = 0.160). Similarly, in cases without evi-
dence of VPI, there was no significant advantage
associated with chemotherapy treatment (Figure 2D),
while in VPI+ cases there was a significant treat-
ment-associated benefit (Figure 2E, 3-year OS 34.2%
versus 58.5% log-rank P = 0.003). Predominant
growth pattern also shows a strong relationship: low-
and intermediate-risk groups (LPA/APA/PPA) see no
significant benefit (Figure 2F,G), while high-risk cate-
gories (SPA/MPPA) do (Figure 2H, 3-year OS 29.7%
versus 55.6% log-rank P = 0.004). Details of all
matched patient groups are supplied (Table S5).
Unmatched analyses were conducted in parallel
(Figure S5; Table S6). No chemotherapy effect was
seen in models which include all patients, consistent
with selection bias, as patients receiving AC are of
sex male reference
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Figure 1. Forest plot showing multivariate Cox model of overall survival by key clinicopathological and clinical variables.
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Overall survival for all cases: AC status
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Figure 2. Kaplan–Meier analyses of chemotherapy effects in low- and high-risk pathological subgroups. AC cases were matched with non-
AC cases by propensity score matching. (A) All cases, (B) vascular invasion negative, (C) vascular invasion positive, (D) visceral pleural inva-
sion negative (PL0), (E) visceral pleural invasion positive (PL1–3), (F) low-risk predominant growth pattern (LPA) (G) intermediate-risk pre-
dominant growth patterns (APA/PPA) and (H) high-risk predominant growth patterns (SPA/MPPA).
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more advanced stage. Subgroup analysis, however,
shows VI patients trending toward a poorer out-
come with chemotherapy treatment (HR = 1.108,
P = 0.673) but a better outcome in VI+ patients
(HR = 0.753, P = 0.151). Similarly, VPI patients
only see a negative effect of chemotherapy
(HR = 1.435, P = 0.111) while VPI+ patients experi-
ence a benefit (HR = 0.539, P = 0.007). When ana-
lysing groups by predominant pattern, only high-risk
SPA/MPPA categories show a significant trend
toward improved survival (HR = 0.552, P = 0.046).
Hypothetically, therefore, the inclusion of any or
all of these high-risk features as AC selection criteria
might be expected to improve survival outcomes for
these patient groups.
In order to test this idea retrospectively, we con-
structed a further series of matched models to com-
pare the current stage-based inclusion criteria (i.e.
stage IIA/IIB/IIIA) and alternative expanded criteria
which included additional high-risk patient cate-
gories. Each model compared two groups of patients:
those who met model criteria and received
chemotherapy, and those who met model criteria and
did not receive chemotherapy (Figure 3). Thus, these
models assess treatment efficacy within different sub-
groups of patients. Allotment of patients for
chemotherapy is governed by many factors in
addition to stage, such as fitness, post-operative com-
plications and patient choice, so that it is not unusual
for patients not to receive adjuvant therapy despite
meeting stage criteria.
Figure 3A shows the performance of the current
criteria, in which patients receiving AC experience an
early benefit (3-year OS 42.2% versus 56.5% Peto &
Peto P = 0.011) although this is attenuated over time
(5-year OS 25.8% versus 38.1% log-rank P = 0.025).
The addition of any single additional high-risk crite-
rion results in a beneficial treatment effect and
improves 5-year survival for AC patients (Figure 3B–
D). Inclusion of all three variables has a dramatic
effect, showing a 17.6% 3-year survival benefit for
AC-treated patients, Peto & Peto P = 0.003, and
13.8% 5-year survival benefit for AC-treated patients,
log-rank P = 0.005 (Figure 3E). Equivalent
unmatched models were also created in which the
benefits of criteria expansion are still apparent in the
treated groups, although the cost of withholding
treatment is less apparent (Figure S6), suggestive of a
treatment selection bias. So, not only do single patho-
logical high-risk features AC benefit, but their inclu-
sion in AC criteria alongside stage appears to improve
survival of treated groups.
What benefit of AC can we discern in the subgroup
of patients who show only VI+/VPI+/high-risk
Table 2. Summary of univariate Cox models for overall survival comparing patients treated with AC versus untreated
patients after propensity score matching
Clinicopathological variable




(treated versus untreated) Hazard ratio 95% CI P-value
All patients 84 versus 84 43 versus 57 0.572 0.385, 0.851 0.001
Vascular invasion (VI)
Negative 36 versus 36 16 versus 24 0.604 0.320, 1.137 0.118
Positive 48 versus 48 27 versus 30 0.692 0.411, 1.167 0.167
Visceral pleural invasion (VPI)
Negative 43 versus 43 22 versus 25 0.761 0.429, 1.350 0.35
Positive 41 versus 41 21 versus 31 0.442 0.253, 0.771 0.004
WHO subtype
LPA 7 versus 7 0 versus 2 5.075e-10 0, Inf 0.999
APA/PPA 50 versus 50 31 versus 38 0.683 0.425, 1.098 0.115
SPA/MPPA 27 versus 27 12 versus 20 0.364 0.177, 0.749 0.006
LPA, Lepidic adenocarcinoma; APA, Acinar adenocarcinoma; PPA, Papillary adenocarcinoma; SPA, Solid adenocarcinoma; MPPA, Micropap-
illary adenocarcinoma.
© 2021 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology, 78, 838–848.
844 M Sereno et al.
predominant growth pattern but who do not other-
wise qualify for AC under current stage-only criteria?
A further model was constructed to test this. 170
patients (159 of which have complete treatment data)
meet this description, but unsurprisingly the number
who received AC is small (n = 8). However, in both
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Figure 3. Kaplan–Meier analysis of patient survival comparing AC versus non-AC outcomes for existing and augmented sets of AC criteria.
AC cases were matched with non-AC cases by propensity score matching. (A) Current stage-based criteria (i.e. overall stage IIA/IIB/IIIA),
(B) Stage or VI+, (C) Stage or VPI+, (D) Stage or MPPA/SPPA and (E) Stage or VI+/VPI+/SPA/MPPA.
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matched and unmatched analyses (Figures S7 and
S8), this group showed evidence of a highly signifi-
cant treatment benefit compared to poor prognosis of
untreated groups (0 deaths in 8 cases). We were
unable to find any additional variables not used for
matching which might help to explain the excellent
survival of this small group (e.g. younger age, lower
smoking history) (Table S7). This preliminary finding
illustrates the possibility that a sizeable group of
patients who are currently not considered for AC
may be being under-treated. However, given the
extremely small size of the group the observation
must be treated with caution, especially as it has
major implications for therapy. The inclusion of
patients displaying these additional high-risk features
in addition to stage would greatly increase the num-
ber of non-mucinous lung cancer cases meeting crite-
ria for AC, increasing the proportion from 51.0% to
84.0% of our cohort (Figure S9).
Discussion
The introduction of AC into surgical practice for
NSCLC has greatly improved patient outcomes. How-
ever, compared to other common malignancies, the
current stage-based criteria for the consideration of
treatment in lung cancer appear somewhat simplistic.
In colon cancer, lymphovascular invasion and poorly
differentiated growth are both recommended inclu-
sion criteria in stage II disease.10 In breast cancer,
multiple tumour features, including proliferation rate
and histological grade are routinely integrated along-
side stage by decision-to-treat tools such as the PRE-
DICT algorithm.11 It is plausible that lung cancer
patients might also benefit from the inclusion of some
high-risk pathological features, and while some allow-
ance is made for this in the US National Comprehen-
sive Cancer Network (NCCN) guidelines it is
supported by lower-level evidence only.12
A previous high-profile study has addressed the use
of predominant growth pattern as a predictor of likely
benefit from AC,13 finding in a large pooled analysis
of published AC trials that high-risk predominant
growth pattern predicts good disease-specific out-
comes. Crucially, our own findings, performed with
very different methodology, confirm that high-risk
predominant growth patterns are predictive of good
AC effects. Moreover, in addition to high-risk predom-
inant growth patterns, our data suggest that two
other histopathological predictors of nodal metastasis
and early death, namely VI+ and VPI+, are also
potent predictors of AC benefit.
There is as yet no formal grading scheme in lung
adenocarcinoma. VPI is a component of TNM staging,
having been adopted for the 7th edition of TNM in
200914 and retained in the 8th edition in 2016.15
However, it does not direct high-risk patients towards
AC, as it upstages from T1 to T2a, which in the
absence of nodal involvement is stage group IB, and
therefore not currently recommended for AC.
In our set of 620 cases, 170 showed the presence
of VI+/VPI+/high-risk predominant growth pattern in
the absence of advanced clinical stage. 8 actually
received adjuvant chemotherapy; we do not know
why, but it is possible that the presence of high-risk
pathological features might have prompted this,
despite not being part of current UK guidelines.
Suggestively, their survival was very much better
than a matched group. This suggests that patients
falling into this subgroup may not only benefit from
AC, but may be especially likely to benefit, perhaps
because metastases derived from these early-stage
tumours are less likely to be well established and are
present a greater chance of elimination by AC. Inter-
estingly, previous studies have suggested that earlier-
stage tumours may benefit from AC,16 and our find-
ings would suggest that this observation may be dri-
ven partly by the presence of additional high-risk
features.
We acknowledge the limitations of our single-cen-
tre retrospective approach: the number of cases over-
all, and especially of AC cases is relatively small. We
would have liked to include recurrence-free survival
data as an additional endpoint, but unfortunately as
the data were collected retrospectively, we did not
detect enough recurrence events to be powered.
There is no true patient randomisation, and we do
not know the full details of chemotherapy regimens
applied or the decision-making processes behind
them. However, our approach brings the major
advantage that it has been possible to collect key
pathological data that have not been widely consid-
ered for their value as predictive biomarkers in this
context. The problem of selection bias was amelio-
rated by the use of a case matching approach to ret-
rospectively simulate study randomisation. Despite
this, and especially given the major increase in the
use of adjuvant chemotherapy which our findings
might suggest, we stress that these findings are
exploratory in nature.
Reassuringly, this study recapitulates several key
findings from other studies, such as the independent
prognostic value of VI, VPI, and predominant growth
pattern, the overall benefit of AC under current selec-
tion criteria, and the finding that subtype
© 2021 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology, 78, 838–848.
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classification predicts chemotherapy benefit.13 Fur-
thermore, the biological rationale for the use of addi-
tional high-risk histopathological features in AC
administration is strong. Therefore, we think it rea-
sonable that VI, VPI, and predominant growth pat-
tern may have potential in the future to generally
predict AC benefit in lung adenocarcinoma. Further-
more, our results lend additional support to the rec-
ommendation in the US NCCN guidelines that high-
risk factors may be considered in the decision to offer
AC in resected stage IB/IIA NSCLC.
However, as they stand our observations remain
exploratory and preliminary in nature. They should
be tested in a suitably designed randomised prospec-
tive study with a sound histopathological footing and
careful recording of recurrence as an endpoint. The
implications in other subtypes of NSCLC, especially
squamous cell carcinoma, also need to be examined.
If validated, these proposed modifications would be
wide-reaching, suggesting that many additional
patients ought to be considered for post-operative
chemotherapy for the best chance of long-term sur-
vival.
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Supporting Information
Additional Supporting Information may be found in
the online version of this article:
Table S1. Summary of univariate Cox models for
overall survival (all cases).
Table S2. Summary of univariate Cox models for
overall survival (untreated cases only).
Table S3. Pearson’s Chi-squared test of association
between each pair of clinicopathological variables.
Table S4. Goodman and Kruskal’s tau measure of
association between each pair of clinicopathological
variables.
Table S5. Summary demographics for all propensity
score matched analysis groups (treated versus non-
treated cases).
Table S6. Summary of univariate Cox models for
overall survival comparing patients treated with AC
versus untreated patients before propensity score
matching.
Table S7. Demographics and clinicopathological
details of the 11 patients treated with AC who show
only VI+/VPI+/high-risk predominant growth pattern
but who do not otherwise qualify for AC under cur-
rent stage-only criteria.
Table S8. Continued: Demographics and clinico-
pathological details of the 8 treated patients who
show only VI+/VPI+/high-risk predominant growth
pattern but who do not otherwise qualify for AC
under current stage-only criteria.
Figure S1. Kaplan–Meier analyses of overall sur-
vival by simplified pathological subgroups in the
entire cohort of 620 patients.
Figure S2. Kaplan–Meier analyses of overall sur-
vival by simplified pathological subgroups in patients
who did not receive AC.
Figure S3. Kaplan–Meier analyses of overall sur-
vival by detailed pathological subgroups in the entire
cohort of 620 patients.
Figure S4. Kaplan–Meier analyses of overall sur-
vival by detailed pathological subgroups in patients
who did not receive AC.
Figure S5. Unmatched Kaplan–Meier analyses of
chemotherapy effects in low- and high-risk pathologi-
cal subgroups.
Figure S6. Unmatched Kaplan–Meier analysis of
patient survival comparing AC- versus non-AC out-
comes for existing and augmented sets of AC criteria.
Figure S7. Matched Kaplan–Meier analysis of
chemotherapy effects in cases showing high-risk
histopathological features (VI+/VPI+/SPA/MPPA) but
not meeting current stage-based criteria.
Figure S8. Unmatched Kaplan–Meier analysis of
chemotherapy effects in cases showing high-risk
histopathological features (VI+/VPI+/SPA/MPPA) but
not meeting current stage-based criteria.
Figure S9. Comparison of the proportion of non-
mucinous lung adenocarcinoma cases meeting exist-
ing and augmented criteria for the consideration of
AC.
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